Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Middle Yanchang Road, Shanghai, 200072, China.
Department of Cardiology, Qidong People's Hospital, Qidong, Jiangsu, China.
J Transl Med. 2023 Jan 12;21(1):21. doi: 10.1186/s12967-022-03859-w.
Growth arrest-specific 6 (GAS6) is a vitamin K-dependent protein related to inflammation, fibrosis, as well as platelet function. Genetic ablation of GAS6 in mice protects against cardiac hypertrophy and dysfunction. Nonetheless, the association between plasma GAS6 levels and acute heart failure (AHF) patients is still unknown.
We measured plasma GAS6 concentrations in 1039 patients with AHF who were enrolled in the DRAGON-HF trial (NCT03727828). Mean follow-up of the study was 889 days. The primary endpoint is all-cause death.
In total, there were 195 primary endpoints of all-cause death and 135 secondary endpoints of cardiovascular death during the mean follow-up duration of 889 days. The higher levels of GAS6 were associated with higher rates of all-cause and cardiovascular death (P < 0.05). Baseline plasma GAS6 levels were still strongly correlated with clinical outcomes in different models after adjustment for clinical factors and N-terminal pro-brain natriuretic peptide (NT-proBNP, P < 0.05). GAS6 could further distinguish the risks of clinical outcomes based on NT-proBNP measurement.
Elevated plasma GAS6 levels were associated with an increased risk of all-cause and cardiovascular death in patients with AHF. Trial registration NCT03727828 (DRAGON-HF trial) clinicaltrials.gov.
生长停滞特异性基因 6（GAS6）是一种维生素 K 依赖性蛋白，与炎症、纤维化以及血小板功能有关。在小鼠中敲除 GAS6 基因可预防心肌肥厚和功能障碍。然而，血浆 GAS6 水平与急性心力衰竭（AHF）患者之间的关系尚不清楚。
我们测量了 1039 例 AHF 患者的血浆 GAS6 浓度，这些患者均纳入 DRAGON-HF 试验（NCT03727828）。研究的平均随访时间为 889 天。主要终点是全因死亡。
在平均 889 天的随访期间，共有 195 例全因死亡的主要终点和 135 例心血管死亡的次要终点。较高的 GAS6 水平与全因死亡和心血管死亡的发生率较高相关（P<0.05）。在调整临床因素和 N 端脑利钠肽前体（NT-proBNP）后，基线血浆 GAS6 水平与不同模型中的临床结局仍密切相关（P<0.05）。GAS6 可进一步根据 NT-proBNP 测量结果区分临床结局的风险。
在 AHF 患者中，血浆 GAS6 水平升高与全因死亡和心血管死亡的风险增加相关。试验注册 NCT03727828（DRAGON-HF 试验）clinicaltrials.gov。
